• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

因院前直接口服抗凝治疗而入院的重症监护病房患者的抗凝处方模式:单学术中心经验

Anticoagulation Prescribing Patterns in Intensive Care Unit Patients Admitted with Prehospital Direct Oral Anticoagulant Therapy: A Single Academic Center Experience.

作者信息

Lal Amos, Mukhtar Osama, Chalmers Sarah J, Karp John, Wieruszewski Patrick M, Park John G

机构信息

Mayo Clinic, Rochester, MN, USA.

Royal College of Surgeons, Dublin, Ireland.

出版信息

Hosp Pharm. 2023 Feb;58(1):84-91. doi: 10.1177/00185787221122656. Epub 2022 Sep 4.

DOI:10.1177/00185787221122656
PMID:36644754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9837329/
Abstract

OBJECTIVE

To describe the current prescribing practices of direct oral anticoagulants (DOACs) in intensive care unit (ICU) patients and the associated clinical outcomes, including the incidence of major bleeding episodes and the need for intervention (endoscopic, surgical, or interventional radiology guided).

DESIGN

Observational, retrospective chart review.

SETTING AND PARTICIPANTS

Single large academic center study. Participants included patients with critical illness who were admitted to the intensive care units (ICU) at Mayo Clinic from January 1st, 2012, until May 4th, 2018. Adult ICU patients with a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) listed as one of the active medications at the time of hospital admission were included.

RESULTS

37 249 patients in medical and surgical intensive care units were screened for the study period. After excluding patients who did not qualify, 558 unique encounters were included. The median age was 69 (IQR 59-78) years; most patients were male, white Caucasians, and had a median SOFA score of 4. After excluding the patients who had major bleeding episodes in the first 24 hours, 188 (39%) were continued on the same DOAC therapy, 204 (42%) were discontinued without transitioning to another agent, and 95 (20%) were transitioned to another agent. Finally, 410 (84%) were dismissed on DOAC therapy at the end of hospitalization. The difference in the continuation rate of the same DOAC agent beyond 24 hours, discontinuation without transition to an alternate agent, or discontinuation of DOAC with a transition to an alternate anticoagulation agent was not statistically significant ( = .60). A total of 52 major bleeding events were identified. Gastrointestinal bleeding was the most common bleeding complication [n (%): 34 (65)], followed by intra-abdominal and peri-procedural bleeding [7 (13.5) and 7 (13.5)]. Thirty-three (65%) patients had a major bleeding complication requiring intervention.

CONCLUSIONS

Our single-center retrospective study describes the current prescribing practices and preliminary outcomes in ICU patients with prehospital use of DOACs. Up to 20% of the patients were transitioned to a different agent within 24 hours of ICU admission, whereas a significant proportion of patients (42%) had anticoagulation discontinued altogether. Most patients who suffered a major bleeding episode required either endoscopic or surgical intervention to control bleeding.

摘要

目的

描述重症监护病房(ICU)患者直接口服抗凝剂(DOACs)的当前处方实践及相关临床结局,包括大出血事件的发生率以及干预需求(内镜、手术或介入放射学引导下的干预)。

设计

观察性、回顾性病历审查。

设置与参与者

单一大型学术中心研究。参与者包括2012年1月1日至2018年5月4日期间入住梅奥诊所重症监护病房(ICU)的危重症患者。纳入在入院时将DOAC(阿哌沙班、利伐沙班、达比加群或依度沙班)列为活性药物之一的成年ICU患者。

结果

在研究期间对37249名内科和外科重症监护病房患者进行了筛查。排除不符合条件的患者后,纳入了558例独特病例。中位年龄为69岁(四分位间距59 - 78岁);大多数患者为男性、白种人,中位序贯器官衰竭评估(SOFA)评分为4分。排除在最初24小时内发生大出血事件的患者后,188例(39%)继续使用相同的DOAC治疗,204例(42%)停药且未转换为其他药物,95例(20%)转换为其他药物。最终,410例(84%)患者在住院结束时继续接受DOAC治疗。24小时后相同DOAC药物的继续使用率、未转换为替代药物而停药或停用DOAC并转换为替代抗凝药物之间的差异无统计学意义(P = 0.60)。共确定了52例大出血事件。胃肠道出血是最常见的出血并发症[n(%):34(65)],其次是腹腔内和围手术期出血[7(13.5)和7(13.5)]。33例(65%)患者发生大出血并发症需要干预。

结论

我们的单中心回顾性研究描述了ICU患者院前使用DOACs的当前处方实践和初步结局。高达20%的患者在入住ICU后24小时内转换为不同药物,而相当比例的患者(42%)完全停用了抗凝药物。大多数发生大出血事件的患者需要内镜或手术干预来控制出血。

相似文献

1
Anticoagulation Prescribing Patterns in Intensive Care Unit Patients Admitted with Prehospital Direct Oral Anticoagulant Therapy: A Single Academic Center Experience.因院前直接口服抗凝治疗而入院的重症监护病房患者的抗凝处方模式:单学术中心经验
Hosp Pharm. 2023 Feb;58(1):84-91. doi: 10.1177/00185787221122656. Epub 2022 Sep 4.
2
Pre-hospital use of direct oral anticoagulants agents is associated with a lower risk of major bleeding events in critically ill patients: A single academic center experience.院前使用直接口服抗凝剂与危重症患者大出血事件风险较低相关:一项单学术中心经验。
Heart Lung. 2023 Nov-Dec;62:264-270. doi: 10.1016/j.hrtlng.2023.08.008. Epub 2023 Aug 24.
3
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病:治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
4
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.综述文章:直接口服抗凝剂与胃肠道出血风险
Cardiovasc Drugs Ther. 2022 Oct;36(5):973-989. doi: 10.1007/s10557-021-07211-0. Epub 2021 Jun 18.
5
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.直接口服抗凝剂治疗患者的胃肠道出血严重程度。
Am J Med. 2018 May;131(5):573.e9-573.e15. doi: 10.1016/j.amjmed.2017.11.007. Epub 2017 Nov 22.
6
Characteristics, treatment and outcome of bleeding after tooth extraction in patients on DOAC and phenprocoumon compared to non-anticoagulated patients-a retrospective study of emergency department consultations.比较直接口服抗凝药(DOAC)和华法林抗凝治疗与非抗凝治疗患者拔牙后出血的特征、治疗和结局:一项急诊科会诊的回顾性研究。
Clin Oral Investig. 2019 May;23(5):2273-2278. doi: 10.1007/s00784-018-2676-7. Epub 2018 Oct 5.
7
Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants.直接口服抗凝剂治疗胃肠道出血住院患者的再出血与血栓栓塞。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1893-1900.e2. doi: 10.1016/j.cgh.2018.05.005. Epub 2018 Jun 30.
8
Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.直接口服抗凝药物治疗方案的处方实践比较。
Am J Cardiovasc Drugs. 2017 Dec;17(6):475-479. doi: 10.1007/s40256-017-0243-2.
9
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动患者华法林、达比加群、阿哌沙班或利伐沙班抗凝治疗的大出血风险。
J Manag Care Spec Pharm. 2017 Sep;23(9):968-978. doi: 10.18553/jmcp.2017.23.9.968.
10
Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia.评价直接口服抗凝剂在肝素诱导的血小板减少症管理中的应用。
J Thromb Thrombolysis. 2022 Nov;54(4):597-604. doi: 10.1007/s11239-022-02705-6. Epub 2022 Sep 21.

引用本文的文献

1
Evaluation of direct oral anticoagulant continuation versus switching to a parenteral anticoagulant in critically ill patients: a retrospective cohort study.危重症患者中直接口服抗凝剂持续使用与转换为肠外抗凝剂的评估:一项回顾性队列研究。
Thromb J. 2025 Mar 10;23(1):20. doi: 10.1186/s12959-025-00703-1.
2
Association between critical care admission and chronic medication discontinuation post-hospital discharge: A retrospective cohort study.重症监护病房入院与出院后慢性药物停用之间的关联:一项回顾性队列研究。
J Intensive Care Soc. 2024 Mar 1;25(3):255-265. doi: 10.1177/17511437241230260. eCollection 2024 Aug.
3
Septic shock definitions and associated outcomes in blood culture positive critically ill patients.血培养阳性的重症患者中脓毒症休克的定义及相关结局
Ann Transl Med. 2023 Mar 15;11(5):192. doi: 10.21037/atm-22-5147. Epub 2023 Feb 24.

本文引用的文献

1
Use of direct oral anticoagulants in ICU patients. Part II - Clinical evidence.ICU 患者中直接口服抗凝剂的应用。第二部分 - 临床证据。
Anaesthesiol Intensive Ther. 2021;53(5):440-449. doi: 10.5114/ait.2021.110608.
2
The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines.直接口服抗凝剂用于癌症相关静脉血栓栓塞的预防或治疗:一项荟萃分析及指南综述
Thromb J. 2021 Oct 30;19(1):76. doi: 10.1186/s12959-021-00326-2.
3
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.2021年欧洲心律协会心房颤动患者使用非维生素K拮抗剂口服抗凝药实用指南。
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
4
Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.直接口服抗凝剂在心力衰竭合并心房颤动患者中的出血风险。
Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2):e007230. doi: 10.1161/CIRCOUTCOMES.120.007230. Epub 2021 Feb 5.
5
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
6
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.住院内科患者中直接口服抗凝剂与低分子肝素的比较:一项为2018年美国血液学会指南提供依据的系统评价和荟萃分析
Blood Adv. 2020 Apr 14;4(7):1512-1517. doi: 10.1182/bloodadvances.2019000840.
7
Is there a role for low-dose DOACs as prophylaxis?低剂量 DOAC 作为预防措施是否有作用?
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):187-193. doi: 10.1182/hematology.2019000026.
8
Direct-Acting Oral Anticoagulants in Critically Ill Patients.直接口服抗凝剂在危重症患者中的应用。
Chest. 2019 Sep;156(3):604-618. doi: 10.1016/j.chest.2019.05.025. Epub 2019 Jun 25.
9
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会与胸外科医师协会合作报告
Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28.
10
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).在临床实践中,非维生素K拮抗剂口服抗凝剂与华法林治疗心房颤动患者大出血的管理比较(来自心房颤动更明智治疗结果登记处[ORBIT-AF II]的第二阶段)
Am J Cardiol. 2017 May 15;119(10):1590-1595. doi: 10.1016/j.amjcard.2017.02.015. Epub 2017 Mar 28.